Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002106 · ClinicalTrials.gov registry record · Phase 2
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
A Phase 2 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT00002106 is a Phase 2 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 104 participants.
The verdict
NCT00002106, a Phase 2 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
Interventions
- DRUG Ranitidine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002106
The ClinicalTrials.gov registry entry for NCT00002106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranitidine hydrochloride is the first listed.
NCT00002106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002106 about?
NCT00002106 is a clinical study titled "A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3". To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
What is the current status of trial NCT00002106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants.
What interventions are being tested in trial NCT00002106?
The interventions under investigation include: Ranitidine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002106?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.